对于克罗恩病中的维多利祖马布疗效进行分层患者分析:在EVOLVE研究中识别最佳子组以提高治疗反应
Andres Yarur1, Gerassimos J Mantzaris2, Song Wang3
1Cedars Sinai Medical Center, 8700 Beverly Blvd. Ste AC1128, Los Angeles, CA, USA. ajyarur@gmail.com.
Advances in therapy
|April 24, 2024
概括
维多利祖马布在一些生物原始的克罗恩病患者中显示出比抗瘤缩因子α (抗TNFα) 药物更快的临床缓解.
科学领域:
- 胃肠病学和肝病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩病 (CD) 管理包括生物疗法.
- 维多利祖马布和抗瘤坏死因子α (抗TNFα) 药物是关键的治疗选择.
- 确定从特定药物中获益最多的患者亚群至关重要.
研究的目的:
- 为了比较vedolizumab与抗TNFα药物的疗效,在没有生物治疗的CD患者中.
- 为了确定特定的患者亚组,他们可能会从vedolizumab中获得更大的好处.
- 制定简化规则来识别这些有利的亚群.
主要方法:
- 现实世界EVOLVE队列研究的回顾性分析.
- 包括使用维多利祖马布 (n=195) 或抗TNFα剂 (n=245) 治疗的生物原始的CD患者.
- 开发用于临床缓解和效果得分的预测模型;用于规则开发的分类树分析.
主要成果:
- 总的来说,与抗TNFα (11.1个月) 相比,维多利祖马布的临床缓解时间中位数较短 (7.8个月).
- 在前40%的预测响应者中,维多利祖马布显著更快缓解 (4.8个月) 与抗TNFα (18.1个月) 相比.
- 一项简化规则将正在进行的CD恶化,没有先前的急诊和没有限制性疾病的患者确定为可能的vedolizumab响应者.
结论:
- 确定了生物原始的CD患者的特定亚群,在这些亚群中,vedolizumab可能比抗TNFα药物更有效地实现临床缓解.
- 简化临床规则可以帮助识别那些可能从vedolizumab中获益更多的患者.
- 建议进行进一步的验证研究,以确认这些发现和规则.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
Inflammatory Bowel Disease II: Crohn's Disease
222
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
222
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


